Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIOMET for accelerated maturation in girls
2024-518675-55-00Phase 2Authorised
- Sponsor
- Hospital Universitari de Girona Dr. Josep Trueta
- Start
- Oct 2024
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in precocious puberty and polycystic ovary syndrome (PCOS) comparing SPIOMET with Placebo (2 arms). Primary endpoint: Bone age advancement at 0–1 year. Planned start Oct 2024; status: authorised.
02
Drugs
spironolactone + pioglitazone + metformin
03
Conditions
precocious pubertypolycystic ovary syndrome (PCOS)
Beyond the preview
Go deeper on 2024-518675-55-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518675-55-00.